Back

Lower income is associated with non-persistence to statin treatment after a first myocardial infarction

28 August 2023 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention Secondary Prevention ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Mr Kevin Ma

Karolinska Institute, Stockholm (Sweden)

8 More presentations in this session

Presentation thumbnail
Real world prognostic impact and predictors of adherence to statin therapy after STEMI on first year follow up: results from the FAST STEMI registry
Doctor L. Carmagnola (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Long-term aspirin adherence and risk of cardiovascular events and death after myocardial infarction: A nationwide cohort study
Doctor A. Kristensen (Frederiksberg, DK)
Abstract Slides Video
Presentation thumbnail
A global perspective on cardiovascular risk factor management in patients with CHD and different educational level: SURF CHD II
Ms A. Marza Florensa (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Lipid assessment and achievement of secondary prevention european society of cardiology guideline targets in patients with atherosclerotic cardiovascular disease with and without depression
Doctor R. Summers (Swansea, GB)
Abstract Slides Video
Presentation thumbnail
The effect of implementing a guideline-based approach to achieve target LDL-C levels in very high risk patients. The PENELOPE study one year follow-up results.
Mr S. Van Der Brug (Breda, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention

The Event

Event poster

ESC Congress 2023

28 August 2023 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Medication persistence and mortality in SWEDEHEART STEMI patients with and without standard modifiable risk factors
thumbnail
Congress Presentation
Treatment patterns and adherence to lipid-lowering drugs during 8 years of follow-up after a cardiovascular event
thumbnail
Congress Presentation
High rates of discontinuation and reinitiation of secondary preventive medications after a first myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources